These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 26064049)

  • 1. Comparison of paroxetine and agomelatine in depressed type 2 diabetes mellitus patients: a double-blind, randomized, clinical trial.
    Kang R; He Y; Yan Y; Li Z; Wu Y; Guo X; Liang Z; Jiang J
    Neuropsychiatr Dis Treat; 2015; 11():1307-11. PubMed ID: 26064049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Agomelatine might be more appropriate for elderly, depressed, type 2 diabetes mellitus patients than paroxetine/fluoxetine.
    Liang Z; Jia Y; Zhao L; Zhu R; He X; Tong B; Yang F; Hao L; Cui P; Yuan J
    Aging (Albany NY); 2021 Oct; 13(19):22934-22946. PubMed ID: 34610580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Agomelatine versus fluoxetine in glycemic control and treating depressive and anxiety symptoms in type 2 diabetes mellitus subjects: a single-blind randomized controlled trial.
    Che T; Teng X; Huang Q; Mu Y; Tang X; Mu X; Wei Y
    Neuropsychiatr Dis Treat; 2018; 14():1527-1533. PubMed ID: 29942131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Agomelatine versus paroxetine in treating depressive and anxiety symptoms in patients with chronic kidney disease.
    Chen JW; Xie SQ
    Neuropsychiatr Dis Treat; 2018; 14():547-552. PubMed ID: 29497298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Agomelatine and sertraline for the treatment of depression in type 2 diabetes mellitus.
    Karaiskos D; Tzavellas E; Ilias I; Liappas I; Paparrigopoulos T
    Int J Clin Pract; 2013 Mar; 67(3):257-60. PubMed ID: 23409693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale.
    Montejo AL; Prieto N; Terleira A; Matias J; Alonso S; Paniagua G; Naval S; Parra DG; Gabriel C; Mocaër E; Portolés A
    J Psychopharmacol; 2010 Jan; 24(1):111-20. PubMed ID: 18801825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence-Based Pharmacotherapy of Anxiety Symptoms in Patients with Major Depressive Disorder: Focus on Agomelatine.
    Stein DJ
    Neurol Ther; 2023 Apr; 12(Suppl 1):13-19. PubMed ID: 37115460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severity of depression and anxiety are predictors of response to antidepressant treatment in Parkinson's disease.
    Moonen AJ; Wijers A; Leentjens AF; Christine CW; Factor SA; Juncos J; Lyness JM; Marsh L; Panisset M; Pfeiffer R; Rottenberg D; Serrano Ramos C; Shulman L; Singer C; Slevin J; McDonald W; Auinger P; Richard IH
    Parkinsonism Relat Disord; 2014 Jun; 20(6):644-6. PubMed ID: 24679737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind, multicenter study in primary care comparing paroxetine and clomipramine in patients with depression and associated anxiety. Paroxetine Study Group.
    Ravindran AV; Judge R; Hunter BN; Bray J; Morton NH
    J Clin Psychiatry; 1997 Mar; 58(3):112-8. PubMed ID: 9108813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression.
    Baldwin DS; Hawley CJ; Abed RT; Maragakis BP; Cox J; Buckingham SA; Pover GH; Ascher A
    J Clin Psychiatry; 1996; 57 Suppl 2():46-52. PubMed ID: 8626363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mirtazapine compared with paroxetine in major depression.
    Benkert O; Szegedi A; Kohnen R
    J Clin Psychiatry; 2000 Sep; 61(9):656-63. PubMed ID: 11030486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine.
    Baldwin D; Bridgman K; Buis C
    J Psychopharmacol; 2006 Jan; 20(1):91-6. PubMed ID: 16204325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of Paroxetine 20 mg daily in the treatment of depression and depression associated anxiety.
    Chaudhry HR; Qureshi Z; Tareen IA; Yazdani I
    J Pak Med Assoc; 2002 Nov; 52(11):518-25. PubMed ID: 12585372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II).
    McElroy SL; Weisler RH; Chang W; Olausson B; Paulsson B; Brecher M; Agambaram V; Merideth C; Nordenhem A; Young AH;
    J Clin Psychiatry; 2010 Feb; 71(2):163-74. PubMed ID: 20122366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial.
    Kim JE; Yoon SJ; Kim J; Jung JY; Jeong HS; Cho HB; Shin E; Lyoo IK; Kim TS
    Int J Clin Pract; 2011 Mar; 65(3):323-9. PubMed ID: 21314870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients.
    De Wilde J; Spiers R; Mertens C; Bartholomé F; Schotte G; Leyman S
    Acta Psychiatr Scand; 1993 Feb; 87(2):141-5. PubMed ID: 8447241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence.
    Le Noury J; Nardo JM; Healy D; Jureidini J; Raven M; Tufanaru C; Abi-Jaoude E
    BMJ; 2015 Sep; 351():h4320. PubMed ID: 26376805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy of escitalopram vs paroxetine on severe depression with associated anxiety: data from the "Boulenger" study].
    Chauvet-Gélinier JC
    Encephale; 2010 Oct; 36(5):425-32. PubMed ID: 21035633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of depression on quality of life of patients with type II diabetes mellitus.
    Eren I; Erdi O; Sahin M
    Depress Anxiety; 2008; 25(2):98-106. PubMed ID: 17311266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lavender oil preparation Silexan is effective in generalized anxiety disorder--a randomized, double-blind comparison to placebo and paroxetine.
    Kasper S; Gastpar M; Müller WE; Volz HP; Möller HJ; Schläfke S; Dienel A
    Int J Neuropsychopharmacol; 2014 Jun; 17(6):859-69. PubMed ID: 24456909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.